Accelmed
VC Fund
Aventura, United States
Accelmed is a venture capital firm that funds private and public medical device companies with significant market potential and proven clinical data.Concentrating on medical device companies that have already reached the revenue stage enables the firm to assist companies in benefiting from its managerial capabilities and financial resources.Together with the management teams of their portfolio companies, the Accelmed can steer the way from the clinical-stage to a profitable business with a clear commercial plan, thereby accelerating the path to a successful exit.In 2009, Mori Arkin and Uri Geiger, the co-founders of Accelmed, established the firm in Herzliya, Tel Aviv.
- Total investments:
- 41
- Last investment:
- Lead investor:
- 46%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Accelmed invests in
Stages Accelmed invests in
Countries Accelmed invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $695k–$24M
- Series D
- $13M–$96M
Investment Focus
Industry
- Health Care 27 (66%)
- Medical Device 19 (46%)
- Medical 9 (22%)
- Biotechnology 7 (17%)
- Health Diagnostics 5 (12%)
Stage
- Funding Round 7 (17%)
- Series D 6 (15%)
- Series A 5 (12%)
- Series B 4 (10%)
- Post-IPO Equity 4 (10%)
Country
- United States 15 (37%)
- Israel 13 (32%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gilad Rotem
Medical Analyst
|
Medical Analyst | Total investments: 0 | Find email | |
Lior Shav
Private Equity Investment Manager
|
Private Equity Investment Manager | Total investments: 0 | Find email | |
Michal Fisher
IP Consultant
|
IP Consultant | Total investments: 0 | Find email | |
Uri Geiger
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 16 | Find email | |
Camilo Rico
Vice President
|
Vice President | Total investments: 1 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Corvia Medical
|
Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts. | $55M / Jun 17, 2025 | |
UltraClear
|
UltraClear is a skincare clinic that provides facial rejuvenation solutions for the treatment of all skin types. | $23M / Series B / May 29, 2025 | |
GT Medical Technologies
|
GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. | $53.3M / Series D / Jan 16, 2025 | |
Revamp Medical
|
Revamp medical was founded in 2016 with the goal of resolving one of the most urgent unmet needs in Acute Heart Failure patients. Targeting a market of >1M annual admissions in the US with a direct cost of $65B, Revamp is set to deliver an easily adoptable solution using its patented temporary catheter, Doraya™.Revamp has a seasoned team ofprofessionals with a proven track record in leading multiple med-tech startups. | Series A / May 30, 2023 | |
Minerva Surgical
|
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which aredesigned to address the most common causes of abnormal uterine bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. | $30M / Post-IPO Equity / Dec 27, 2022 | |
MedMinder Systems
|
MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists withnotifications about their dosage activity, which can be monitored remotely through a patient profile on MedMinder's website.The company was founded in 2007 and is headquartered in Needham, Massachusetts. | $25M / Debt Financing / Aug 30, 2022 | |
|
MedMinder Systems
|
MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists withnotifications about their dosage activity, which can be monitored remotely through a patient profile on MedMinder's website.The company was founded in 2007 and is headquartered in Needham, Massachusetts. | $10M / Venture - Series Unknown / Aug 24, 2022 | |
Veranex
|
Veranex is the first truly end-to-end, global, tech-enabled, concept-through-commercialization service provider that focuses solely on medical technology: medical device, diagnostics, companion diagnostics, digital health, and drug delivery. For all your needs through the entire medical device clinical trial process, Veranex is transforming medtechinnovations. | Private Equity / May 19, 2022 | |
Click Therapeutics
|
Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive datascience platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. | $52M / Series B / Oct 22, 2021 | |
Keystone Dental
|
Keystone Dental was founded in March 2006, and aspires to build a market leading, global brand recognized within the dental community for its integrity, trust and commitment to improving the standard of care for patients and their quality of life. Since then, they have rapidly grown into a diversely skilled, fast-moving team of professionalscommitted to providing excellent customer service and producing high-quality products and services. | $25M / Venture - Series Unknown / Sep 01, 2021 | |
| See all 41 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Accelmed invest in?
Accelmed invests primarily in Health Care, Medical Device and Medical startups, most often at Funding Round and Series D stage. Most of the 41 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Accelmed's check size?
Accelmed typically joins rounds of $695k–$24M at Series A and $13M–$96M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Accelmed participates in.
How do I contact Accelmed?
Public channels for Accelmed include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Accelmed?
The team at Accelmed includes Gilad Rotem (Medical Analyst), Lior Shav (Private Equity Investment Manager) and Michal Fisher (IP Consultant), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
